Blanks R G, Bennett R L, Wallis M G, Moss S M
Cancer Screening Evaluation Unit, Block D, Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK.
J Med Screen. 2002;9(1):11-4. doi: 10.1136/jms.9.1.11.
The size (number of women screened) of the 95 individual NHS breast screening programmes (NHSBSPs) varies by a factor of 10. This study investigates the impact of size on the performance of individual programmes.
Data were collated from the 95 United Kingdom screening programmes on the standard statistical returns for the past 5 years (1 April 1995-31 March 2000). Additional information was obtained from questionnaires. The number of women screened between 1 April 1999 and 31 March 2000 determined the size of a programme. The bottom 25% were defined as small, the middle 50% as medium, and the top 25% as large. On average large programmes screened about four times as many women as small programmes and medium programmes about twice as many. Performance was evaluated using cancer detection rates, referral rates for assessment, and positive predictive value (PPV) of assessment using PPV referral diagrams.
The performance of smaller programmes was shown to be marginally poorer than medium and large sized programmes in that they detected fewer cancers and had a lower PPV. The smallest 25% of programmes had an invasive cancer detection rate 13% less than the medium and large programmes. However, if these programmes had an equivalent detection rate to the medium/large programmes the national detection rate would only increase by about 2%. This is because the 75% of programmes described as medium and large screen about 90% of all women. It is therefore important to place the clinical importance of these findings in context when considering any envisaged possible solutions.
Although the performance of smaller programmes was shown to be poorer than that of the larger programmes, it is not clear from this study exactly why this is so. A likely contributory factor based on experience of evaluating the NHSBSP is that performance problems in larger programmes have been easier to detect by quality assurance staff. The size of the small programmes and the few screen detected cancers (and inherent statistical instability in detection rates) mean that problems are difficult to identify. As a consequence small programmes which are genuinely performing marginally below specific standards are likely to receive less attention than larger programmes, and even under close scrutiny the causes are less likely to be found.
95个国民保健服务乳房筛查项目(NHSBSPs)的规模(接受筛查的女性人数)相差达10倍。本研究调查规模对各项目绩效的影响。
整理来自英国95个筛查项目过去5年(1995年4月1日至2000年3月31日)的标准统计报表数据。通过问卷调查获取额外信息。1999年4月1日至2000年3月31日期间接受筛查的女性人数确定项目规模。规模最小的25%被定义为小型项目,中间的50%为中型项目,规模最大的25%为大型项目。平均而言,大型项目筛查的女性人数约为小型项目的四倍,中型项目约为小型项目的两倍。使用癌症检出率、评估转诊率以及利用PPV转诊图评估的评估阳性预测值(PPV)来评估绩效。
规模较小的项目绩效略逊于中型和大型项目,因为它们检出的癌症较少且PPV较低。规模最小的25%的项目浸润性癌症检出率比中型和大型项目低13%。然而,如果这些项目的检出率与中型/大型项目相当,全国检出率仅会提高约2%。这是因为被描述为中型和大型的75%的项目筛查了约90%的所有女性。因此,在考虑任何设想的可能解决方案时,将这些发现的临床重要性置于背景中很重要。
尽管规模较小的项目绩效被证明比规模较大的项目差,但本研究尚不清楚确切原因。根据评估NHSBSP的经验,一个可能的促成因素是质量保证人员更容易发现大型项目中的绩效问题。小型项目的规模以及筛查出的癌症数量较少(以及检出率中固有的统计不稳定性)意味着问题难以识别。因此,真正绩效略低于特定标准的小型项目可能比大型项目受到的关注更少,而且即使经过仔细审查,也不太可能找到原因。